Heart Failure in Ischemic Stroke: Relevance for Acute Care and Outcome.
Acute Disease
Aged
Aged, 80 and over
Brain Ischemia
/ complications
Cerebral Revascularization
Disease-Free Survival
Female
Heart Failure
/ etiology
Humans
Intracranial Hemorrhages
/ etiology
Male
Mechanical Thrombolysis
Prospective Studies
Registries
Stroke
/ complications
Survival Rate
Time Factors
Tissue Plasminogen Activator
/ administration & dosage
heart failure
humans
registries
telephone
thrombectomy
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
29
9
2019
medline:
31
3
2020
entrez:
28
9
2019
Statut:
ppublish
Résumé
Background and Purpose- Heart failure (HF) in patients with acute ischemic stroke constitutes the source of various detrimental pathophysiologic mechanisms including prothrombotic and proinflammatory states, worsening of cerebral tissue oxygenation, and hemodynamic impairment. In addition, HF might affect the safety and efficacy of the acute recanalization stroke therapies. Methods- Patients treated with intravenous recombinant tissue-type plasminogen activator or mechanical recanalization at a universitary stroke center were included into a prospective registry. Patients received cardiological evaluation, including echocardiography, during acute care. Functional outcome was assessed after 90 days by structured telephone interviews. Safety and efficacy of intravenous thrombolysis and mechanical thrombectomy were investigated among patients with HF and compared with patients with normal cardiac function after propensity score matching. Results- One thousand two hundred nine patients were included. HF was present in 378 patients (31%) and an independent predictor of unfavorable functional outcome. Recanalization rates were equal among patients with HF after intravenous thrombolysis and after mechanical recanalization or combined treatment. The rate of secondary intracranial hemorrhage was not different (7% versus 8%;
Identifiants
pubmed: 31558143
doi: 10.1161/STROKEAHA.119.026139
doi:
Substances chimiques
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM